Repositioning Immunotherapy in VetArans With Lung Cancer
This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Mar 2, 2026 · Source: ClinicalTrials.gov
The study is currently accepting participants.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- VA Office of Research and Development
- Interventions being studied
- Drug: Nivolumab
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Patient must have a performance status of 0-1 (ECOG Performance Scale)
- Patient must be a candidate for concurrent chemoradiation
- Unresectable Stage III NSCLC as assessed by investigator or multidisciplinary tumor board assessment
- PD-L1 tumor expression greater than or equal to 1%
- Presence of measurable disease according to RECIST v1.1
- Adequate organ function
- Available tissue (archival FFPE preferred) with adequate tumor content ( 20% tumor cellularity)
- Active autoimmune disease that has requires immunosuppressive therapy in the previous year
- Uncontrolled primary or acquired immunodeficiency (including HIV)
- Baseline corticosteroid usage (\>10 mg prednisone or equivalent daily) aside from supportive medication use
- Tumor with known EGFR, ALK, ROS1, MET or RET mutations/fusions
- Presence of significant comorbidities precluding participation in a clinical study as determined by investigator
- Prior thoracic radiotherapy or prior systemic treatment for stage IIIB/IV NSCLC
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
- Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with informed consent through 180 days after the last dose of trial treatment
- Has a known history of active TB (Bacillus Tuberculosis)
- Has known active Hepatitis B or Hepatitis C
- Has received a live vaccine within 30 days of enrollment
- Known diagnosis of Interstitial Lung Disease
- Inability to provide informed consent
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- VA Connecticut Healthcare System West Haven Campus, West Haven, CTWest Haven, Connecticut
- VA Central Office, Washington, DCWashington D.C., District of Columbia
- Richard L. Roudebush VA Medical Center, Indianapolis, INIndianapolis, Indiana
- VA Ann Arbor Healthcare System, Ann Arbor, MIAnn Arbor, Michigan
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NEOmaha, Nebraska
- Michael E. DeBakey VA Medical Center, Houston, TXHouston, Texas
- Richmond VA Medical Center, Richmond, VARichmond, Virginia
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 2, 2026. Always confirm current availability with the study team.